REVANCE THERAPEUTICS INC (RVNC)
US7613301099 - Common Stock
Commit To Buy Revance Therapeutics At $2.50, Earn 20.9% Annualized Using Options
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Snatch Shares of RVNC 12.5% Cheaper Than the CEO Did
Top Buys by Top Brass: CEO Foley's $209.4K Bet on RVNC
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock
Revance Announces Proposed Public Offering of Common Stock
Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update
Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024
Revance to Participate in Upcoming Investor Conferences
Investors growing more bullish on SMID cap biotech stocks (NASDAQ:ALNY)
Investors are more bullish about small and mid-cap biotech stocks this year, with Merus (MRUS) and Fusion (FUSN) viewed as most likely to outperform, according to TD Cowen.
Revance jumps as Daxxify reimbursement simplified with permanent J-code (NASDAQ:RVNC)
Revance Therapeutics' stock surged 15% after securing a permanent J-code for its Daxxify injection, approved to treat frown lines and cervical dystonia,...
Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®
Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference
Revance falls after Mizuho downgrades citing "too high guidance" (NASDAQ:RVNC)
Revance Therapeutics (RVNC) shares fell 3.5% premarket after Mizuho cut its recommendation on the stock from "Buy" to "Neutral". With the stock trading at ~$6,
AbbVie sees maintaining Botox position in aesthetics: report (NYSE:ABBV)
Despite increasing competition, AbbVie reportedly expects Botox to maintain its leading market share position in the aesthetics market. Read more here.
Commit To Buy Revance Therapeutics At $5, Earn 32.5% Annualized Using Options
Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook
Noteworthy Tuesday Option Activity: TSCO, RVNC, DKS
Revance Therapeutics files for mixed shelf (NASDAQ:RVNC)
Revance Therapeutics files a mixed shelf offering, but the prospectus does not disclose the amount. This is not an offer to sell securities.